Abstract Allergic rhinitis (AR) is a widespread chronic condition caused by immune responses involving immunoglobulin E (IgE) when exposed to airborne allergens. It frequently coexists with conditions such as asthma and eye inflammation and represents a major public health issue due to its significant burden and associated disabilities across the globe. Key contributing factors include exposure to airborne or workplace-related allergens and hereditary predispositions. AR negatively impacts daily life, including social interactions, academic performance, and productivity at work, while also leading to considerable economic expenses. The ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines categorize AR based on duration (intermittent or persistent) and severity (mild or moderate/severe). Diagnosis primarily relies on clinical evaluation, and in patients with uncontrolled or long-term symptoms, confirmation may involve skin prick testing or detecting specific IgE antibodies in the blood. Common treatments include oral, nasal, or eye-drop antihistamines (H1-blockers), nasal corticosteroids, or a combination of both delivered intranasally. Allergen-specific immunotherapy, administered by qualified specialists and using standardized extracts, is beneficial for individuals with ongoing symptoms. Insights from real-life data collected through mobile applications are enhancing understanding of AR types and their management. Future developments aim to improve recognition of complex overlapping conditions, utilize health technology evaluations, and promote patient-involved treatment decisions.
Mishra et al. (Mon,) studied this question.